Julie Kanter Washko, MD
Pediatric Hematology-Oncology · Birmingham, ALNPI 1902071368
Payments from drug & device makers
Across 293 payments — averaging $4343.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$742K
- Takeda Pharmaceuticals U.S.A., Inc.$170K
- Genetix Biotherapeutics Inc$163K
- Pfizer$25K
- Global Blood Therapeutics, Inc.$22K
- Chiesi USA, Inc.$17K
- plus $135K from 26 others
Across 25 payments — averaging $1124.05 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$15K
- Novartis Pharma AG$7K
- Pfizer$6K
- Sanofi US Services Inc.$544
- Novo Nordisk$125
What the payments were for
- Consulting fees$178,69965%
- Speaking & faculty fees$37,57314%
- Travel & lodging$52,68619%
- Food & beverage$4,4212%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 91 | $741,760 |
| Takeda Pharmaceuticals U.S.A., Inc. | 76 | $169,676 |
| Genetix Biotherapeutics Inc | 14 | $162,812 |
| Pfizer | 10 | $25,081 |
| Global Blood Therapeutics, Inc. | 4 | $21,512 |
| Chiesi USA, Inc. | 9 | $16,611 |
| Terumo BCT, Inc. | 13 | $15,335 |
| Octapharma USA, Inc. | 5 | $15,306 |
| Novo Nordisk AS | 4 | $14,083 |
| Apo-pharma Inc. | 4 | $12,918 |
| Sanofi | 5 | $10,498 |
| Bioverativ Therapeutics Inc. | 8 | $7,991 |
| Novo Nordisk Health Care AG | 4 | $6,770 |
| Gamida Cell Inc. | 3 | $5,625 |
| Sanofi-aventis U.S. LLC | 2 | $5,593 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $5,395 |
| Agios Pharmaceuticals, Inc. | 9 | $5,162 |
| Novartis Pharma AG | 1 | $4,575 |
| Merck | 1 | $4,270 |
| E.r. Squibb & Sons, L.L.C. | 6 | $3,815 |
| Bristol Myers Squibb | 1 | $2,600 |
| Acelrx Pharmaceuticals, Inc. | 1 | $2,500 |
| Ironwood Pharmaceuticals, Inc | 5 | $2,375 |
| GSK | 1 | $2,000 |
| Vertex | 5 | $1,949 |
| F. Hoffmann-la Roche AG | 1 | $1,640 |
| Bio Products Laboratory USA, Inc. | 1 | $1,500 |
| Tersera Therapeutics LLC | 1 | $1,392 |
| Biocodex, Inc. | 1 | $1,000 |
| Janssen Research & Development, LLC | 1 | $715 |
| Novo Nordisk | 2 | $247 |
| Medunik USA Inc. | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ADAKVEO$104,935
- FERRIPROX$11,345
- SKYSONA$8,840
- Zynteglo$8,840
- Spectra Optia$8,414
- NO PRODUCT DISCUSSED$7,783
- Spectra Optia Apheresis System$6,713
- APHEXDA$5,625
- XIFAXAN$5,395
- Reblozyl$2,600
- DSUVIA$2,500
- PYRUKYND$1,576
- Gammaplex$1,500
- QUZYTTIR$1,392
- OXBRYTA$116
How this compares
$1,272,726 in reported general payments places this provider in the 95th percentile of 38 pediatric hematology-oncology providers in Alabama.
See all pediatric hematology-oncology providers in Alabama →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ferriprox (2 Times A Day)Deferiprone | 59 | $1,409,079 |
| Deferiprone (3 Times A Day)Deferiprone | 54 | $676,388 |
| ProcritEpoetin Alfa | 44 | $381,719 |
| FerriproxDeferiprone | 18 | $312,675 |
| Deferasirox | 111 | $274,998 |
| OxbrytaVoxelotor | 18 | $145,776 |
| ZubsolvBuprenorphine Hcl/Naloxone Hcl | 42 | $47,055 |
| SiklosHydroxyurea | 26 | $43,880 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 191 | $27,312 |
| EliquisApixaban | 31 | $18,803 |
| OxycontinOxycodone Hcl | 27 | $17,460 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 406 | $6,070 |
| Methadone Hcl | 299 | $3,665 |
| Hydromorphone Hcl | 308 | $3,133 |
| Hydroxyurea | 133 | $2,839 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Chiesi USA, Inc.Ferriprox (2 Times A Day), Ferriprox | $16,611 | $1,721,75577 claims |
| Global Blood Therapeutics, Inc.Oxbryta | $21,512 | $145,77618 claims |
| PfizerEliquis | $25,081 | $18,80331 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 38 pediatric hematology-oncology providers in Alabama.
Other pediatric hematology-oncology in Birmingham
- Todd CooperBirmingham$2.8M
- Matthew KutnyBirmingham$1.2M
- Chibuzo IlonzeBirmingham$681K
- Thomas HowardBirmingham$593K
- Ana XavierBirmingham$320K
- Frederick GoldmanBirmingham$238K
- Jeffrey LebensburgerBirmingham$185K
- Girish DhallBirmingham$177K
- Joseph ChewningBirmingham$157K
- Aman WadhwaBirmingham$100K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.